التفاصيل البيبلوغرافية
| العنوان: |
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029. |
| المؤلفون: |
Salous, Tareq, Shukla, Nikhil A., Althouse, Sandra K., Perkins, Susan M., Furqan, Muhammad, Leal, Ticiana, Traynor, Anne M., Feldman, Lawrence E., Hanna, Nasser H., Durm, Greg A. |
| المصدر: |
Cancer (0008543X); Jan2023, Vol. 129 Issue 2, p264-271, 8p |
| مصطلحات موضوعية: |
NON-small-cell lung carcinoma, PROGRAMMED cell death 1 receptors, PROGRAMMED death-ligand 1, CANCER research, SQUAMOUS cell carcinoma |
| الشركة/الكيان: |
BIG Ten Conference (U.S.) |
| مستخلص: |
Background: Immunotherapy using a checkpoint inhibitor (CPI) alone or in combination with chemotherapy is the standard of care for treatment‐naive patients with advanced non–small cell lung cancer (NSCLC) without driver mutations for which targeted therapies have been approved. It is unknown whether continuing CPI treatment beyond disease progression results in improved outcomes. Methods: Patients who experienced progressive disease (PD) after a clinical benefit from chemotherapy plus a CPI were enrolled. Patients received pembrolizumab (200 mg every 3 weeks) plus next‐line chemotherapy. The primary end point was progression‐free survival (PFS) according to the Response Evaluation Criteria in Solid Tumors (version 1.1). Key secondary end points included the overall survival (OS), clinical benefit rate, and toxicity. The authors' hypothesis was that continuing pembrolizumab beyond progression would improve the median PFS to 6 months in comparison with a historical control of 3 months with single‐agent chemotherapy alone. Results: Between May 2017 and February 2020, 35 patients were enrolled. The patient and disease characteristics were as follows: 51.4% were male; 82.9% were current or former smokers; and 74.3%, 20%, and 5.7% had adenocarcinoma, squamous cell carcinoma, and NSCLC not otherwise specified, respectively. The null hypothesis that the median PFS would be 3 months was rejected (p <.05). The median PFS was 5.1 months (95% confidence interval [CI], 3.6–8.0 months). The median OS was 24.5 months (95% CI, 15.6–30.9 months). The most common treatment‐related adverse events were fatigue (60%), anemia (54.3%), and nausea (42.9%). There were no treatment‐related deaths. Conclusions: Pembrolizumab plus next‐line chemotherapy in patients with advanced NSCLC who experienced PD after a clinical benefit from a CPI was associated with statistically significant higher PFS in comparison with historical controls of single‐agent chemotherapy alone. Pembrolizumab plus next‐line chemotherapy in patients with advanced non–small cell lung cancer who experienced progressive disease after a clinical benefit from a checkpoint inhibitor was associated with statistically significant higher progression‐free survival in comparison with a historical control of single‐agent chemotherapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer (0008543X) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder